Severe gastritis due to pembrolizumab treatment in a lung cancer patient

The incidence of immune checkpoint inhibitor (ICI) ‐induced gastritis is relatively rare, compared with colitis, but a massive immunoreaction caused by ICIs can induce severe gastritis. Thus, gastritis should be considered when patients taking ICIs complain of any gastrointestinal symptoms. AbstractImmune checkpoint inhibitors (ICIs) are known to induce gastrointestinal adverse events. Colitis occurs most frequently, and gastritis is less common. A few case reports of gastritis induced by ICIs have indicated that colitis induced by cytotoxic T ‐lymphocyte antigen‐4 (CTLA‐4) resembles inflammatory bowel disease (IBD) and that programmed death‐1/programmed death ligand‐1 (PD‐1/PD‐L1) inhibitor can also induce the same type of colitis. We herein encountered a case of gastritis arising after 25 cycles of pembrolizumab administ ration in which the pathological and endoscopic findings resembled those of IBD. ICIs may induce gastritis in a manner similar to the pathogenesis of IBD.

Source: Respirology Case Reports - July 29, 2020 Category: Respiratory Medicine Authors: Noriko Hayama, Hiroaki Ihara, Yuichirou Honma, Yukinari Itoigawa, Kyoichi Kaira, Mitsuhiro Fujii Tags: Case Report Source Type: research